Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr 26:10.1002/cbic.201800017.
doi: 10.1002/cbic.201800017. Online ahead of print.

FaptaSyme: A Strategy for Converting a Monomer/Oligomer-Nonselective Aptameric Sensor into an Oligomer-Selective One

Affiliations

FaptaSyme: A Strategy for Converting a Monomer/Oligomer-Nonselective Aptameric Sensor into an Oligomer-Selective One

Baggio A Evangelista et al. Chembiochem. .

Abstract

Aptameric sensors can bind molecular targets and produce output signals, a phenomenon that is used in bioassays. In some cases, it is important to distinguish between monomeric and oligomeric forms of a target. Here, we propose a strategy to convert a monomer/oligomer-nonselective sensor into an oligomer-selective sensor. We designed an aptazyme that produced a high fluorescent output in the presence of oligomeric α-synuclein (a molecular marker of Parkinson's disease) but not its monomeric form. The strategy is potentially useful in the design of point-of-care tests for the diagnosis of neurodegenerative diseases.

Keywords: aptamers; aptazymes; biosensors; deoxyribozymes; split probes.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Design of split aptazyme (SAptaz) sensor for the detection of α-synuclein (α-syn). A) A catalytic DNA oligonucleotide, DZ-10–23, can cleave a fluorophore- and a quencher-labeled fluorogenic substrate (F_sub). A position for splitting the DZ as discovered by Mokany et al.[10] is indicated by the red arrow. B) Split aptazyme design strategy: both DZ and the aptamer DNA strands are split into two parts. Each half of the aptamer is linked to one-half of DZ to form SAptz-1a and SAptz-1b strands, which form the catalytic DZ core when aptameric portions bind α-syn (see Figure S1 for more details). C) Selectivity of α-syn recognition by the split SAptaz-1 sensors. All samples contained 200 nM F_sub, 2 nM SAptz-1a, 50 nM SAptz-1b, and either no protein target (Noise) or 100 nM either oligomeric or monomeric α-syn, or 26 μM of thrombin (Negative control).
Figure 2.
Figure 2.
Full-Aptamer-Split-DNAzyme (FaptaSyme) sensor design and performance. A) Design strategy: only the DZ sequence is split in half; each segment is linked to a full aptamer sequence. FaptaSyme-a and FaptaSyme-b strands bind α-syn by their aptameric portions and form a DZ catalytic core followed by fluorescent signaling. In both cases, DZ and aptameric portions were linked by oligoethylene glycol linkers (dashed lines). B) Selectivity of α-syn recognition by the FaptaSyme sensor. All samples contained 200 nM F_sub, 2 nM FaptaSyme-a, 50 nM FaptaSyme-b, and either no protein target (Noise) or 100 nM oligomeric or monomeric α-syn, or 26 μM of thrombin (Negative control). The concentrations of FaptaSyme were optimized, as detailed in Figure S2.

Similar articles

Cited by

References

    1. Ellington AD and Szostak JW, Nature 1990, 346, 818–22; - PubMed
    2. Mercier MC, Dontenwill M and Choulier L, Cancers (Basel) 2017, 9; - PMC - PubMed
    3. Sefah K, Phillips JA, Xiong X, Meng L, Van Simaeys D, Chen H, Martin J and Tan W, Analyst 2009, 134, 1765–1775; - PubMed
    4. Pfeiffer F, Rosenthal M, Siegl J, Ewers J and Mayer G, Curr Opin Biotechnol 2017, 48, 111–118; - PubMed
    5. Reverdatto S, Burz DS and Shekhtman A, Curr Top Med Chem 2015, 15, 1082–1101. - PMC - PubMed
    1. Thean D, Ebo JS, Luxton T, Lee XC, Yuen TY, Ferrer FJ, Johannes CW, Lane DP and Brown CJ, Sci Rep 2017, 7, 1763; - PMC - PubMed
    2. Ding F, Gao Y and He X, Bioorg Med Chem Lett 2017, 27, 4256–4269; - PubMed
    3. Farzin L, Shamsipur M and Sheibani S, Talanta 2017, 174, 619–627; - PubMed
    4. Alizadeh N, Memar MY, Moaddab SR and Kafil HS, Biomed. Pharmacother 2017, 93, 737–745; - PubMed
    5. Tang J, Huang N, Zhang X, Zhou T, Tan Y, Pi J, Pi L, Cheng S, Zheng H and Cheng Y, Int. J. Nanomedicine 2017, 12, 3899–3911; - PMC - PubMed
    6. Cho EJ, Lee JW and Ellington AD, Annu. Rev. Anal. Chem. (Palo Alto Calif) 2009, 2, 241–264; - PubMed
    7. Labib M and Berezovski MV, Adv. Biochem. Eng. Biotechnol 2014, 140, 155–181. - PubMed
    1. Stojanovic MN, Kolpashchikov DM. J. Am. Chem. Soc 2004, 126, 9266–9270; - PubMed
    2. Pei R, Rothman J, Xie Y, Stojanovic MN Nucleic Acids Res. 2009, 37, e59; - PMC - PubMed
    3. Strack RL, Song W, Jaffrey Nat SR. Protoc. 2014, 9, 146–155. - PMC - PubMed
    1. Soukup GA and Breaker RR, Proc. Natl. Acad. Sci. U. S. A 1999, 96, 3584–3589; - PMC - PubMed
    2. Vinkenborg JL, Karnowski N and Famulok M, Nat. Chem. Biol 2011, 7, 519–527; - PubMed
    3. Wu D, Gao T, Lei L, Yang D, Mao X and Li G, Anal Chim Acta 2016, 942, 68–73. - PubMed
    1. Yamamoto R, Baba T and Kumar PK, Genes Cells 2000, 5, 389–396; - PubMed
    2. Yamamoto-Fujita R and Kumar PK, Anal. Chem 2005, 77, 5460–5466; - PubMed
    3. Yoshida W, Sode K and Ikebukuro K, Biotechnol. Lett 2008, 30, 421–425; - PubMed
    4. Xu W and Lu Y, Anal Chem 2010, 82, 574–578. - PMC - PubMed
    5. Sosic A, Meneghello A, Cretaio E and Gatto B, Sensors (Basel) 2011, 11, 9426–9441; - PMC - PubMed
    6. Lin Z, Chen L, Zhu X, Qiu B and Chen G, Chem Commun (Camb) 2010, 46, 5563–5565; - PubMed
    7. Yu H, Canoura J, Guntupalli B, Lou X and Xiao Y, Chem. Sci 2017, 8, 131–141; - PMC - PubMed
    8. Yuan B, Zhou Y, Guo Q, Wang K, Yang X, Meng X, Wan J, Tan Y, Huang Z, Xie Q and Zhao X, Chem. Commun 2016, 52, 1590–1593. - PubMed

LinkOut - more resources